FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2031146512> ?p ?o ?g. }

• W2031146512 endingPage "1409" @default.
• W2031146512 startingPage "1404" @default.
• W2031146512 abstract "No AccessJournal of UrologyInvestigative Urology1 Oct 2013Hiding in Plain View: Genetic Profiling Reveals Decades Old Cross Contamination of Bladder Cancer Cell Line KU7 with HeLa Wolfgang Jäger, Yutaka Horiguchi, Jay Shah, Tetsutaro Hayashi, Shannon Awrey, Kilian M. Gust, Boris A. Hadaschik, Yoshiyuki Matsui, Shawn Anderson, Robert H. Bell, Susan Ettinger, Alan I. So, Martin E. Gleave, I-Ling Lee, Colin P. Dinney, Masaaki Tachibana, David J. McConkey, and Peter C. Black Wolfgang JägerWolfgang Jäger Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author , Yutaka HoriguchiYutaka Horiguchi Department of Urology, Tokyo Medical University, Tokyo, Japan More articles by this author , Jay ShahJay Shah Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas More articles by this author , Tetsutaro HayashiTetsutaro Hayashi Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author , Shannon AwreyShannon Awrey Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author , Kilian M. GustKilian M. Gust Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author , Boris A. HadaschikBoris A. Hadaschik Department of Urology, University Hospital Heidelberg, Heidelberg, Germany More articles by this author , Yoshiyuki MatsuiYoshiyuki Matsui Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan More articles by this author , Shawn AndersonShawn Anderson Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author , Robert H. BellRobert H. Bell Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author , Susan EttingerSusan Ettinger Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author , Alan I. SoAlan I. So Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author , Martin E. GleaveMartin E. Gleave Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada Financial interest and/or other relationship with OncoGenex, AstraZeneca, Janssen and Astellas. More articles by this author , I-Ling LeeI-Ling Lee Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas More articles by this author , Colin P. DinneyColin P. Dinney Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas Financial interest and/or other relationship with AstraZeneca and FKD Therapies. More articles by this author , Masaaki TachibanaMasaaki Tachibana Department of Urology, Tokyo Medical University, Tokyo, Japan More articles by this author , David J. McConkeyDavid J. McConkey Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas Financial interest and/or other relationship with Apocell, AstraZeneca and Millenium. More articles by this author , and Peter C. BlackPeter C. Black Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.03.009AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: KU7 is a popular urothelial carcinoma cell line that was isolated from the bladder of a patient at Keio University in 1980. It has subsequently been widely used in laboratories around the world. We describe how routine cell line authentication revealed that KU7 was cross contaminated almost 30 years ago with HeLa, a cervical carcinoma cell line. Materials and Methods: Presumed KU7 clones dating from 1984 to 1999 were provided by M.D. Anderson Cancer Center, Vancouver Prostate Centre, Kyoto University, Tokyo Medical University and Keio University. HeLa was obtained from ATCC®. Genomic DNA was isolated and short tandem repeat analysis was performed at the M.D. Anderson Cancer Center Characterized Cell Line Core Facility, Johns Hopkins University Fragment Analysis Facility and RIKEN BioResource Center, Ibaraki, Japan. Comparative genomic hybridization was performed on a platform (Agilent Technologies, Santa Clara, California) at Vancouver Prostate Centre. Results: The short tandem repeat profile of all KU7 clones was an exact match with that of HeLa. Comparative genomic hybridization of all samples revealed an abundance of shared chromosomal aberrations. Slight differences in some genomic areas were explained by genomic drift in different KU7 clones separated by many years. Conclusions: Our analysis identified that cross contamination of KU7 with HeLa occurred before 1984 at the source institution. All KU7 clones in the urological literature should be considered HeLa and experimental results should be viewed in this light. Our results emphasize the need to authenticate cell lines in oncological research. References 1 : Cancer statistics, 2012. CA Cancer J Clin2012; 62: 10. Google Scholar 2 Steering Committee on Cancer Statistics: Canadian Cancer Statistics 2012. Toronto: Canadian Cancer Society2012. Google Scholar 3 : EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol2011; 59: 997. Google Scholar 4 : Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol2006; 49: 466. Google Scholar 5 : Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol2006; 176: 2414. Link, Google Scholar 6 : Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exp Med1953; 97: 695. Google Scholar 7 : Record of the first physician to see Henrietta Lacks at the Johns Hopkins Hospital: history of the beginning of the HeLa cell line. Am J Obstet Gynecol1997; 176: 227. Google Scholar 8 : Henrietta Lacks, HeLa cells, and cell culture contamination. Arch Pathol Lab Med2009; 133: 1463. Google Scholar 9 : Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer1973; 11: 765. Google Scholar 10 : Studies on cellular adhesiveness in five different culture cell lines derived from carcinoma of the urinary bladder. Keio J Med1982; 31: 127. Google Scholar 11 : Studies on KU-1 and KU-7 cells as an in vitro model of human transitional cell carcinoma of urinary bladder. Hum Cell1988; 1: 78. Google Scholar 12 : Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells. Br J Cancer1997; 762: 206. Google Scholar 13 : SCID mice: a suitable model for experimental studies of urologic malignancies. J Urol1991; 146: 1136. Abstract, Google Scholar 14 : A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. BJU Int2007; 100: 1377. Google Scholar 15 : Genetic markers as tracers in cell culture. Natl Cancer Inst Monogr1967; 26: 167. Google Scholar 16 : Identity of some human bladder cancer cell lines. Nature1983; 301: 429. Google Scholar 17 : HeLa cells 50 years on: the good, the bad and the ugly. Nat Rev Cancer2002; 2: 315. Google Scholar 18 : Notice Regarding Authentication of Cultured Cell Lines. Notice No. NOT-OD-08-017. Bethesda: National Institutes of Health2007. Google Scholar 19 : Cell line misidentification: the beginning of the end. Nat Rev Cancer2010; 10: 441. Google Scholar 20 : Check your cultures! A list of cross-contaminated or misidentified cell lines. Int J Cancer2010; 127: 1. Google Scholar 21 NimbleGen Arrays User Guide: CGH Analysis, Version 6.0. Madison, Wisconsin: Roche NimbleGen2009. Google Scholar 22 : Genetic instability and divergence of clonal populations in colon cancer cells in vitro. J Cell Sci2006; 119: 1477. Google Scholar 23 : Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer. Cancer Res2008; 68: 4506. Google Scholar 24 : Regrowth assay method for quantitative evaluation of drug-induced cell damage in vitro: clarification of cell reduction kinetics of anticancer drugs and differential drug sensitivities of genitourinary cancer cell lines. Keio J Med1981; 30: 141. Google Scholar 25 : Noninvasive detection of bladder cancer in an orthotopic murine model with green fluorescence protein cytology. J Urol2003; 170: 975. Link, Google Scholar 26 : Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther2004; 10: 525. Google Scholar 27 : Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer. J Urol2007; 177: 1900. Link, Google Scholar 28 : In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer. Clin Cancer Res2011; 17: 2788. Google Scholar 29 : Real-time cancer cell tracking by bioluminescence in a preclinical model of human bladder cancer growth and metastasis. Eur Urol2011; 60: 337. Google Scholar 30 : Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest2005; 115: 978. Google Scholar © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byAndersson K (2013) This Month in Investigative UrologyJournal of Urology, VOL. 190, NO. 4, (1155-1156), Online publication date: 1-Oct-2013. Volume 190Issue 4October 2013Page: 1404-1409 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.KeywordsDNA contaminationHeLa cellscarcinomaurotheliumurinary bladderMetricsAuthor Information Wolfgang Jäger Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author Yutaka Horiguchi Department of Urology, Tokyo Medical University, Tokyo, Japan More articles by this author Jay Shah Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas More articles by this author Tetsutaro Hayashi Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author Shannon Awrey Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author Kilian M. Gust Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author Boris A. Hadaschik Department of Urology, University Hospital Heidelberg, Heidelberg, Germany More articles by this author Yoshiyuki Matsui Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan More articles by this author Shawn Anderson Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author Robert H. Bell Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author Susan Ettinger Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author Alan I. So Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author Martin E. Gleave Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada Financial interest and/or other relationship with OncoGenex, AstraZeneca, Janssen and Astellas. More articles by this author I-Ling Lee Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas More articles by this author Colin P. Dinney Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas Financial interest and/or other relationship with AstraZeneca and FKD Therapies. More articles by this author Masaaki Tachibana Department of Urology, Tokyo Medical University, Tokyo, Japan More articles by this author David J. McConkey Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas Financial interest and/or other relationship with Apocell, AstraZeneca and Millenium. More articles by this author Peter C. Black Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2031146512 created "2016-06-24" @default.
• W2031146512 creator A5006702120 @default.
• W2031146512 creator A5009043218 @default.
• W2031146512 creator A5016698641 @default.
• W2031146512 creator A5020403670 @default.
• W2031146512 creator A5025235382 @default.
• W2031146512 creator A5025788173 @default.
• W2031146512 creator A5030468520 @default.
• W2031146512 creator A5037149092 @default.
• W2031146512 creator A5041743195 @default.
• W2031146512 creator A5050196540 @default.
• W2031146512 creator A5054731898 @default.
• W2031146512 creator A5059536506 @default.
• W2031146512 creator A5062125605 @default.
• W2031146512 creator A5071174564 @default.
• W2031146512 creator A5076002944 @default.
• W2031146512 creator A5077243123 @default.
• W2031146512 creator A5078386378 @default.
• W2031146512 creator A5080606297 @default.
• W2031146512 date "2013-10-01" @default.
• W2031146512 modified "2023-09-24" @default.
• W2031146512 title "Hiding in Plain View: Genetic Profiling Reveals Decades Old Cross Contamination of Bladder Cancer Cell Line KU7 with HeLa" @default.
• W2031146512 cites W162187343 @default.
• W2031146512 cites W1991592535 @default.
• W2031146512 cites W2000257688 @default.
• W2031146512 cites W2002045993 @default.
• W2031146512 cites W2009857031 @default.
• W2031146512 cites W2010960852 @default.
• W2031146512 cites W2023500337 @default.
• W2031146512 cites W2033760586 @default.
• W2031146512 cites W2036580658 @default.
• W2031146512 cites W2058573524 @default.
• W2031146512 cites W2064352891 @default.
• W2031146512 cites W2070468167 @default.
• W2031146512 cites W2088731719 @default.
• W2031146512 cites W2090241022 @default.
• W2031146512 cites W2093555888 @default.
• W2031146512 cites W2094535938 @default.
• W2031146512 cites W2099243020 @default.
• W2031146512 cites W2113001012 @default.
• W2031146512 cites W2125534706 @default.
• W2031146512 cites W2138133517 @default.
• W2031146512 cites W2165948908 @default.
• W2031146512 cites W2342396206 @default.
• W2031146512 cites W2465237713 @default.
• W2031146512 cites W4252563654 @default.
• W2031146512 cites W4361804794 @default.
• W2031146512 cites W3149786887 @default.
• W2031146512 doi "https://doi.org/10.1016/j.juro.2013.03.009" @default.
• W2031146512 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3805942" @default.
• W2031146512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23500642" @default.
• W2031146512 hasPublicationYear "2013" @default.
• W2031146512 type Work @default.
• W2031146512 sameAs 2031146512 @default.
• W2031146512 citedByCount "31" @default.
• W2031146512 countsByYear W20311465122013 @default.
• W2031146512 countsByYear W20311465122014 @default.
• W2031146512 countsByYear W20311465122015 @default.
• W2031146512 countsByYear W20311465122016 @default.
• W2031146512 countsByYear W20311465122017 @default.
• W2031146512 countsByYear W20311465122018 @default.
• W2031146512 countsByYear W20311465122019 @default.
• W2031146512 countsByYear W20311465122020 @default.
• W2031146512 countsByYear W20311465122021 @default.
• W2031146512 countsByYear W20311465122022 @default.
• W2031146512 crossrefType "journal-article" @default.
• W2031146512 hasAuthorship W2031146512A5006702120 @default.
• W2031146512 hasAuthorship W2031146512A5009043218 @default.
• W2031146512 hasAuthorship W2031146512A5016698641 @default.
• W2031146512 hasAuthorship W2031146512A5020403670 @default.
• W2031146512 hasAuthorship W2031146512A5025235382 @default.
• W2031146512 hasAuthorship W2031146512A5025788173 @default.
• W2031146512 hasAuthorship W2031146512A5030468520 @default.
• W2031146512 hasAuthorship W2031146512A5037149092 @default.
• W2031146512 hasAuthorship W2031146512A5041743195 @default.
• W2031146512 hasAuthorship W2031146512A5050196540 @default.
• W2031146512 hasAuthorship W2031146512A5054731898 @default.
• W2031146512 hasAuthorship W2031146512A5059536506 @default.
• W2031146512 hasAuthorship W2031146512A5062125605 @default.
• W2031146512 hasAuthorship W2031146512A5071174564 @default.
• W2031146512 hasAuthorship W2031146512A5076002944 @default.
• W2031146512 hasAuthorship W2031146512A5077243123 @default.
• W2031146512 hasAuthorship W2031146512A5078386378 @default.
• W2031146512 hasAuthorship W2031146512A5080606297 @default.
• W2031146512 hasBestOaLocation W20311465122 @default.
• W2031146512 hasConcept C111919701 @default.
• W2031146512 hasConcept C112570922 @default.
• W2031146512 hasConcept C121608353 @default.
• W2031146512 hasConcept C126322002 @default.
• W2031146512 hasConcept C187191949 @default.
• W2031146512 hasConcept C18903297 @default.
• W2031146512 hasConcept C2777366897 @default.
• W2031146512 hasConcept C2780352672 @default.
• W2031146512 hasConcept C3020745361 @default.
• W2031146512 hasConcept C41008148 @default.
• W2031146512 hasConcept C54355233 @default.
• W2031146512 hasConcept C71924100 @default.

• next